



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Vimpat®

Common Name: Lacosamide

PDL Category: Anticonvulsants

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Carbamazepine	Preferred
Oxcarbazepine	Preferred
Lamictal®	Preferred
Topamax®	Non-Preferred

Summary

Indications and Usage: Partial-onset seizures: Tablets are indicated for adjunctive therapy in patients ≥ 17 years. Injection is indicated as short term replacement when oral administration is not feasible.¹

Mechanism of Action: Exact mechanism of action is unknown. Vimpat® is thought to selectively enhance slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.¹

Dosage Forms: Tablets: 50mg, 100mg, 150mg, and 200mg; Injection, solution: 10mg/ml (20mg single use vial)

Recommended Dosage: Initially, give 50 mg twice daily (100 mg/day). The dose may be increased, based on clinical response and tolerability, at weekly intervals by 100 mg/day given as two divided doses to a daily dose of 200 to 400 mg/day. Vimpat® injection may be given without further dilution or mixed in compatible diluent and should be administered intravenously over a period of 30 to 60 minutes.¹

Common Adverse Drug Reactions: Diplopia, headache, dizziness, nausea.¹

Contraindications: None¹

Manufacturer: UCB, Inc.

Analysis: Vimpat® is a new antiepileptic drug indicated for adjunctive therapy for the treatment of partial-onset seizures for patients over 17 years of age. The primary endpoint in all 3 trials used to gain FDA approval, was a reduction in the frequency of seizures from baseline compared to placebo. A statistically significant decrease in seizure frequency was seen in all 3 trials for Vimpat®. Other anticonvulsants, such as oxcarbazepine and Lamictal®, have efficacy trials with similar endpoints when compared with placebo. Preferred alternatives appear on the Preferred Drug List, which have similar clinical efficacy and are more cost effective. Some of the preferred alternatives also have an indication for monotherapy and for pediatric use. Therefore, it is recommended that Vimpat® be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Vimpat® [package insert]. Smyrna, GA: UCB, Inc.; 2008.